Kourbeti IS, Maslow MJ
Infectious Diseases Section, VA-New York Harbor Health Care System and the Department of Internal Medicine, New York University School of Medicine, 423 East 23rd Street, New York, NY, 10010, USA.
Curr Infect Dis Rep. 2000 Jun;2(3):193-200. doi: 10.1007/s11908-000-0035-7.
There is an increasing appreciation for the role of nontuberculous mycobacteria (NTM) as pathogens causing pulmonary disease, disseminated disease, or both in immunocompetent and immunocompromised individuals. Species previously considered nonpathogenic have been shown to cause pulmonary infection. The majority of immunocompetent patients with NTM pulmonary infection have underlying lung disease. New diagnostic techniques such as gene probes, gas-liquid and high-pressure chromatography, and polymerase chain reaction offer significant advantages in the rapid identification of NTM species. Some of these techniques allow identification of mycobacteria directly from clinical specimens. The fluoroquinolones, rifabutin, and newer macrolides offer advances in the treatment of infections that are caused by NTM and are resistant to the traditional antimycobacterial drugs.
非结核分枝杆菌(NTM)作为病原体在免疫功能正常和免疫功能低下的个体中引起肺部疾病、播散性疾病或两者兼有的作用,越来越受到重视。以前被认为无致病性的菌种已被证明可引起肺部感染。大多数患有NTM肺部感染的免疫功能正常患者都有潜在的肺部疾病。基因探针、气液和高压色谱以及聚合酶链反应等新的诊断技术在快速鉴定NTM菌种方面具有显著优势。其中一些技术可以直接从临床标本中鉴定分枝杆菌。氟喹诺酮类、利福布汀和新型大环内酯类药物在治疗由NTM引起且对传统抗分枝杆菌药物耐药的感染方面取得了进展。